Enzon Pharmaceuticals Inc (ENZN) Major Shareholder Carl C. Icahn Purchases 694,023 Shares
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) major shareholder Carl C. Icahn purchased 694,023 shares of the company’s stock in a transaction on Monday, November 28th. The stock was acquired at an average price of $0.41 per share, with a total value of $284,549.43. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.
Enzon Pharmaceuticals Inc (NASDAQ:ENZN) opened at 0.4719 on Wednesday. The firm has a market cap of $20.86 million and a P/E ratio of 1.3108. The firm has a 50 day moving average of $0.38 and a 200 day moving average of $0.39. Enzon Pharmaceuticals Inc has a 1-year low of $0.35 and a 1-year high of $1.10.
ILLEGAL ACTIVITY NOTICE: This news story was first published by Daily Political and is the propert of of Daily Political. If you are viewing this news story on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The legal version of this news story can be accessed at http://www.dailypolitical.com/2016/11/30/enzon-pharmaceuticals-inc-enzn-major-shareholder-carl-c-icahn-purchases-694023-shares.html.
Enzon Pharmaceuticals Company Profile
Enzon Pharmaceuticals, Inc receives royalty revenues from existing licensing arrangements with other companies primarily related to sales of four marketed drug products: PegIntron, Sylatron, Macugen and CIMZIA. The Company has no clinical operations and limited corporate operations. PegIntron is used both as a monotherapy and in combination with REBETOL (ribavirin) capsules for the treatment of chronic hepatitis C.
Receive News & Ratings for Enzon Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzon Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.